Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR-T therapy takes on deadly brain tumors

NCT ID NCT07318818

Recruiting now Disease control Sponsor: Tasly Pharmaceutical Group Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment called P134 cells for people with recurrent glioblastoma, an aggressive brain cancer that has come back. P134 cells are immune cells engineered to target two proteins (CD44 and CD133) found on tumor cells. The study will enroll 26 adults to find the safest dose and check for side effects, with the goal of seeing whether this approach can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
P134 cells (a type of CAR-T cell therapy that targets CD44 and CD133 proteins on tumor cells)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is a very early, small trial (26 people) focused on safety and dosing. CAR-T cell therapy can cause serious side effects like brain swelling or nerve damage, and it may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA, IDH-WILDTYPE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    RECRUITING

    Beijing, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.